- Stocks
- Pharma & Healthcare
- Beta Drugs
Beta Drugs share price
NSE: BETAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Beta Drugs at a glance
Beta Drugs (NSE: BETA) closed at ₹1,773.00 on 22 Oct 2026, up 5.60% on the day. With a market capitalisation of ₹1,966 Cr, it ranks 1150th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 43.4× trailing earnings, against a return on equity of 16.9% in FY26. Over the past year the share price has risen 3.3%. Its 52-week range is ₹990.10 (25 Feb 2026) to ₹2,807.90 (12 Aug 2026); the last close is 36.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹126 Cr (+25.3% year on year) and net profit ₹16 Cr (+40.9%), on a consolidated basis. Promoters held 59.10% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,966 CrRank 1150 on NSE
- P/E (trailing)
- 43.4×
- Price to book
- 4.93×FY26
- EPS (TTM)
- ₹44.21to Q1 FY27
- ROE
- 16.9%FY26
- ROCE
- 18.0%FY26
- Debt to equity
- 0.6FY26
- Net profit margin
- 10.8%FY26
- Book value / share
- ₹241.46FY26
- 52-week high
- ₹2,807.9012 Aug 2026
- 52-week low
- ₹990.1025 Feb 2026
- 1-year return
- +3.3%
- RSI (14-day)
- 38.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +5.60% | +5.5% | −14.7% | −24.2% | +3.3% |
Beta Drugs quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹88 Cr | ₹94 Cr | ₹100 Cr | ₹103 Cr | ₹87 Cr | ₹94 Cr | ₹126 Cr |
| Revenue YoY | — | — | — | — | −1.2% | +0.2% | +25.3% |
| Net profit | ₹9 Cr | ₹9 Cr | ₹12 Cr | ₹12 Cr | ₹9 Cr | ₹9 Cr | ₹16 Cr |
| Net profit YoY | — | — | — | — | −4.8% | +0.2% | +40.9% |
| Net margin | 10.1% | 9.6% | 11.7% | 11.8% | 9.8% | 9.6% | 13.1% |
| EPS | ₹9.31 | ₹8.95 | ₹11.59 | ₹12.10 | ₹8.40 | ₹8.93 | ₹14.78 |
Beta Drugs financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹116 Cr | ₹184 Cr | ₹227 Cr | ₹296 Cr | ₹362 Cr | — |
| Operating profit | ₹16 Cr | ₹34 Cr | ₹41 Cr | ₹49 Cr | ₹62 Cr | — |
| Net profit | ₹12 Cr | ₹25 Cr | ₹31 Cr | ₹36 Cr | ₹42 Cr | — |
| EPS (₹) | ₹12.00 | ₹26.00 | ₹32.00 | ₹38.00 | ₹42.00 | — |
| Cash from operations | ₹19 Cr | ₹30 Cr | ₹23 Cr | ₹31 Cr | ₹36 Cr | — |
| Total debt | ₹11 Cr | ₹12 Cr | ₹7 Cr | ₹6 Cr | ₹127 Cr | ₹133 Cr |
| Shareholders' equity | ₹69 Cr | ₹92 Cr | ₹123 Cr | ₹157 Cr | ₹197 Cr | ₹245 Cr |
Beta Drugs shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 25 May 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 66.73% | 66.73% | 64.90% | 64.63% | 59.10% | 59.10% |
| Foreign institutions | 0.90% | 0.90% | 1.14% | 1.16% | 2.95% | 1.02% |
| Domestic institutions | 0.26% | 0.29% | 1.90% | 2.15% | 6.01% | 6.23% |
| Non-institutions | 32.11% | 32.07% | 32.07% | 32.06% | 31.93% | 33.65% |
Beta Drugs vs peers
The listed Pharma & Healthcare companies nearest to Beta Drugs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| INDOCOIndoco Remedies | ₹230.55 | +0.74% | −21.9% | ₹2,128 Cr | — | — |
| PANACEABIOPanacea Biotec | ₹335.85 | −1.22% | −24.2% | ₹2,057 Cr | — | — |
| SAKARSakar Healthcare | ₹923.90 | +2.66% | +156.4% | ₹2,056 Cr | 67.6 | — |
| SAIPARENTSai Parenterals | ₹461.90 | −1.31% | — | ₹2,041 Cr | 103.6 | — |
| BETABeta Drugs | ₹1,773.00 | +5.60% | +3.3% | ₹1,966 Cr | 43.4 | — |
| HESTERBIOHester Biosciences | ₹2,165.00 | −0.37% | +25.4% | ₹1,842 Cr | 32 | — |
| WINDLASWindlas Biotech | ₹885.70 | −0.20% | −2.2% | ₹1,828 Cr | 28.4 | — |
Ask anything about Beta Drugs
Pivot answers on the live chart with evidence you can check, and tests strategies against BETA's own history. Try: “Why has BETA moved over the last three months?” · “Backtest a 50-day moving-average crossover on BETA over five years” · “Compare BETA with INDOCO on margins and valuation”
Frequently asked questions about Beta Drugs
What is the share price of Beta Drugs today?
Beta Drugs (NSE: BETA) last closed at ₹1,773.00 on 22 Oct 2026. Its 52-week high is ₹2,807.90 and its 52-week low is ₹990.10.
What is the market cap of Beta Drugs?
Beta Drugs' market capitalisation is ₹1,966 Cr (₹1,966 Cr) at the 22 Oct 2026 close, ranking 1150th among the NSE companies Pivot tracks.
What is the P/E ratio of Beta Drugs?
Beta Drugs trades at a trailing P/E of 43.4. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 67.6.
What is the ROE and ROCE of Beta Drugs?
Return on equity was 16.9% in FY26 and return on capital employed was 18.0% in FY26 (consolidated figures).
Is Beta Drugs a debt-free company?
No. Beta Drugs' debt-to-equity ratio was 0.6 in FY26, with total debt of ₹133 Cr.
What were Beta Drugs' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Beta Drugs reported revenue of ₹126 Cr, +25.3% year on year, and net profit of ₹16 Cr, +40.9% year on year.
How has Beta Drugs stock performed over the last year?
Beta Drugs' share price has risen 3.3% over the past year, −24.2% over three months and −14.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Beta Drugs?
As of 30 Jun 2026: promoters 59.10%, foreign institutions 1.02%, domestic institutions 6.23%, non-institutions 33.65%.
Who are Beta Drugs' competitors?
The listed Pharma & Healthcare companies closest to Beta Drugs by market cap are Indoco Remedies, Panacea Biotec, Sakar Healthcare, Sai Parenterals, Hester Biosciences and Windlas Biotech.
Is Beta Drugs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Beta Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BETA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text